Sonnet BioTherapeutics
SONN
SONN
hedge funds and large institutions have $141K invested in Sonnet BioTherapeutics in 2017 Q3 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
Holders Change
–
Holders Change %
–
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
No buyers this quarter
Top Sellers
| 1 |
UBS Group
Zurich,
Switzerland
|
-$93K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$59K |
| 3 |
IC
Intersect Capital
San Ramon,
California
|
-$39K |
| 4 |
BlackRock
New York
|
-$33K |
| 5 |
EVC
Eidelman Virant Capital
Saint Louis,
Missouri
|
-$24K |
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $49K | -$59K | – | – |
|
|
IC
2
Intersect Capital
San Ramon,
California
| $32K | -$39K | – | – |
|
|
3
BlackRock
New York
| $28K | -$33K | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $16K | -$93K | – | – |
|
5
Bank of America
Charlotte,
North Carolina
| $11K | -$13K | – | – |
|
|
TDC
6
Thompson Davis & Co
Richmond,
Virginia
| $3K | -$3K | – | – |
|
|
EVC
7
Eidelman Virant Capital
Saint Louis,
Missouri
| $2K | -$24K | – | – |
|
8
Morgan Stanley
New York
| – | -$2K | – | – |
|